Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol
FDA requests additional dosing information for the chronic obstructive pulmonary disorder drug, also known as QAB149.
FDA requests additional dosing information for the chronic obstructive pulmonary disorder drug, also known as QAB149.